Based on long experience, Genexine is focusing on the development of new bio drugs that save the lives of patients suffering from diseases and improve their quality of life.
Genexine’s vision of treating patients and improving their quality of life is being practically realized owing to faster and more accurate drug development based on clinical planning and execution, management of clinical trial institutions, and smooth communication with regulatory authorities.
Moreover, we play a central role in collaborating with global partners through the effective use of external resources and active exchange at scientific meetings and academic seminars with domestic and foreign partners and joint venture partners.
Our clinical development capabilities have acted as a compass for bio-venture development strategies based on our experience of conducting around 20 clinical trials, both rapidly and accurately, on healthy adults and patients over the past five years.
| Candidate | Indication | Development Phase | Collaborator |
|---|---|---|---|
|
GX-E4(Efesa®)
Long-acting erythropoietin
|
CKD-induced anemia |
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Commercial
|
|
|
GX-H9
Long-acting hunman growth hormone
|
Pediatric & Adult growth hormone deficiency |
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Commercial
|
|
|
GX-G6
Long-acting GLP-1
|
Type 2 Diabetes / Obesity |
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Commercial
|
|
|
GX-BP1
SOX2 bioPROTAC
|
Lung Squamous Cell Carcinoma(Lung SCC), Solid Tumors |
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Commercial
|
|
|
GX-BP2
STAT3 bioPROTAC
|
Atopic Dermatitis, cancer |
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Commercial
|
|
|
GX-188E
Therapeutic DNA Vaccine for HPV 16/18 genotype
|
Cervical cancer |
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Commercial
|
|
| Head & Neck cancer Investigator-Initiated Trial(IIT) |
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Commercial
|
||
|
GX-I7
Long-acting human interleukin-7
|
Lymphopenia, solid tumors, infectious disease |
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Commercial
|
|
|
GX-P1
Long-acting PD-L1
|
Autoimmune disease, Transplatation |
Preclinical
Phase 1
Phase 2
Phase 3
Commercial
|
|
|
GX-G3
Long-acting G-CSF
|
Neutropenia |
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Commercial
|
|